[{"id":"d0232ee2-cfb8-4d08-8138-198a58818661","acronym":"","url":"https://clinicaltrials.gov/study/NCT05769075","created_at":"2023-03-15T14:02:16.876Z","updated_at":"2024-07-02T16:35:49.864Z","phase":"Phase 1","brief_title":"A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations","source_id_and_acronym":"NCT05769075","lead_sponsor":"TYK Medicines, Inc","biomarkers":" ALK • ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • ALK rearrangement • ALK fusion • ROS1 fusion","tags":["ALK • ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • ALK rearrangement • ALK fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TY-2136b"],"overall_status":"Recruiting","enrollment":" Enrollment 282","initiation":"Initiation: 04/20/2023","start_date":" 04/20/2023","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2023-04-24"}]